Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $47,770.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00. Following the transaction, the chairman owned 3,532,622 shares in the company, valued at approximately $19,853,335.64. This trade represents a 0.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.
• On Monday, April 20th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total value of $23,372.06.
• On Wednesday, April 15th, Jurgi Camblong sold 17,473 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.00, for a total value of $87,365.00.

SOPHiA GENETICS Stock Performance

SOPH opened at $5.83 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The company has a market cap of $489.08 million, a PE ratio of -11.21 and a beta of 0.96. The stock has a 50-day moving average of $5.22 and a 200-day moving average of $5.01. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC boosted its stake in SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the period. Green Alpha Advisors LLC increased its position in SOPHiA GENETICS by 10.8% in the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after buying an additional 4,444 shares during the period. Dimensional Fund Advisors LP increased its position in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the last quarter. Finally, First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analyst Ratings Changes

SOPH has been the topic of a number of recent analyst reports. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $7.50.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.